AU2002357232A1 - Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease - Google Patents

Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease

Info

Publication number
AU2002357232A1
AU2002357232A1 AU2002357232A AU2002357232A AU2002357232A1 AU 2002357232 A1 AU2002357232 A1 AU 2002357232A1 AU 2002357232 A AU2002357232 A AU 2002357232A AU 2002357232 A AU2002357232 A AU 2002357232A AU 2002357232 A1 AU2002357232 A1 AU 2002357232A1
Authority
AU
Australia
Prior art keywords
alzheimer
disease
treatment
peptide isosteres
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002357232A
Other languages
English (en)
Inventor
John Varghese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of AU2002357232A1 publication Critical patent/AU2002357232A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002357232A 2001-12-04 2002-12-03 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease Abandoned AU2002357232A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33656601P 2001-12-04 2001-12-04
US60/336,566 2001-12-04
PCT/US2002/040038 WO2003047576A1 (en) 2001-12-04 2002-12-03 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2002357232A1 true AU2002357232A1 (en) 2003-06-17

Family

ID=23316667

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002357232A Abandoned AU2002357232A1 (en) 2001-12-04 2002-12-03 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease

Country Status (8)

Country Link
US (1) US20050159460A1 (enExample)
EP (1) EP1450795A1 (enExample)
JP (1) JP2005514380A (enExample)
AU (1) AU2002357232A1 (enExample)
BR (1) BR0214731A (enExample)
CA (1) CA2469130A1 (enExample)
MX (1) MXPA04005451A (enExample)
WO (1) WO2003047576A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002478A1 (en) * 2002-06-27 2004-01-08 Elan Pharmaceuticals, Inc. Methods for treating alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
MXPA06012391A (es) * 2004-04-30 2007-01-31 Theraptosis S A Inhibidores de caspasa-2 y sus aplicaciones biologicas.
WO2007002220A2 (en) * 2005-06-21 2007-01-04 Bristol-Myers Squibb Company Aminoacetamide acyl guanidines as beta-secretase inhibitors
WO2007002214A2 (en) * 2005-06-21 2007-01-04 Bristol-Myers Squibb Company Acyl guanidines as beta-secretase inhibitors
WO2009005783A1 (en) * 2007-06-28 2009-01-08 Blanchette Rockefeller Neurosciences Institute Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis
WO2009080773A1 (en) * 2007-12-24 2009-07-02 Dsm Ip Assets B.V. Convergent synthesis of renin inhibitors and intermediates useful therein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
TR199901128T2 (xx) * 1996-11-22 1999-07-21 Elan Pharmaceuticals, Inc. N-(aril/heteroarilasetil) amino asit esterler, bunu ihtiva eden farmas�tik bile�imler ve bu t�r bile�ikler kullanarak �-amiloit peptit sal�n�m�n� ve/veya bunun sentezlenmesini inhibe etme y�ntemleri.
JP2003528071A (ja) * 2000-03-23 2003-09-24 エラン ファーマスーティカルズ インコーポレイテッド アルツハイマー病治療用組成物および方法
ATE302751T1 (de) * 2000-06-30 2005-09-15 Elan Pharm Inc Verbindungen zur behandlung der alzheimerischen krankheit

Also Published As

Publication number Publication date
WO2003047576A1 (en) 2003-06-12
MXPA04005451A (es) 2005-01-14
EP1450795A1 (en) 2004-09-01
JP2005514380A (ja) 2005-05-19
CA2469130A1 (en) 2003-06-12
US20050159460A1 (en) 2005-07-21
BR0214731A (pt) 2004-12-07

Similar Documents

Publication Publication Date Title
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
EP1392287B8 (en) Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
AU2001233299A1 (en) Methods for treating alzheimer's disease
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2003273213A8 (en) Amyloid peptide inactivating enzyme to treat alzheimer's disease
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU2002302238A1 (en) A method of treatment of alzheimer's disease and device therefor
AU2003303141A1 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
AU2002357232A1 (en) Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease
AU2729400A (en) Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
AU2002312667A1 (en) Individualization of therapy with alzheimer's disease agents
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
AU2002327514A1 (en) Application of peptide conjugates to alzheimer's disease
IL172213A0 (en) Compounds useful in the therapy of alzheimer's disease and formulations containing them
AU2003286530A1 (en) Substituted peptides useful in the treatment of alzheimer's disease
AU2002352811A1 (en) Amino diols useful in the treatment of alzheimer's disease
AU2001267826A1 (en) Remedies for alzheimer's disease
AU2001246518A1 (en) A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
AU2002312797A1 (en) Peptide for the diagnosis and therapy of alzheimer's disease
AU2002346015A1 (en) Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
AU2002364885A1 (en) Alzheimer's disease model
AU2002324446A1 (en) Substituted aminoalcohols useful in treatment of alzheimer's disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase